Journal of Clinical Oncology
Articles in this Issue
Serious infections in patients with CLL/SLL treated with combination venetoclax and obinutuzumab compared with those treated with zanubrutinib: A real-world study.
e19026 Background: Given the compromised immune systems of patients with CLL/SLL, there has always been concern about the association between CLL/SLL-dire...
Trade-off preferences in older adults with newly diagnosed acute myeloid leukemia.
1537 Background: Treatment decisions for older adults with acute myeloid leukemia (AML) are highly preference-sensitive, requiring a balance between survi...
The impact of outpatient rehabilitation services on physical function and potential risk of unplanned healthcare utilization.
e23142 Background: Unplanned healthcare use is associated with increased costs and poorer clinical outcomes, making it a critical target for oncology valu...
Differential predictive impact of PD-L1 expression on immunotherapy outcomes and immunophenotype in squamous versus non-squamous NSCLC.
8562 Background: PD-L1 tumor proportion score (TPS) is a key biomarker for immune checkpoint inhibitors (ICIs) efficacy in non-small cell lung cancer (NSC...
Neoadjuvant penpulimab combined with taxanes and carboplatin in triple-negative breast cancer: A single-arm, open-label, multi-center phase II clinical study (neoTAPPL).
588 Background: The integration of immunotherapy with neoadjuvant chemotherapy has been shown to enhance pathologic complete response (pCR) and survival o...
Clinicopathologic and allele-specific analysis of germline <i>ATM</i> alterations in a pan-cancer cohort.
10615 Background: ATM is a tumor suppressor gene involved in DNA repair and telomere maintenance. ATM biallelic pathog...
<i>TP53</i> genomic alterations including targetable <i>TP53</i> Y220C mutation in clinically advanced breast cancer.
1043 Background: Recent studies demonstrating the ability of drugs such as Rezatapopt to target the TP53 Y220C mutation motivated...
Perioperative treatment strategies for gastric cancer: A retrospective real-world study in China.
e16107 Background: Adjuvant chemotherapy with fluoropyrimidine and platinum remains a standard treatment following gastrectomy across Asia. Despite its wi...
Interim safety and efficacy data of [ <sup>212</sup> Pb]VMT01 in MC1R expressing melanoma.
3099 Background: Immune checkpoint inhibitors (ICI) are effective in melanoma, but many patients experience progression on or after approved ICI +/- MAPK...
Current treatment patterns for early breast cancer among healthcare professionals and concordance with expert recommendations: Analysis of an online interactive decision support tool.
1550 Background: The treatment paradigm for HER2-negative early breast cancer (EBC) now includes pembrolizumab and targeted therapies such as olaparib, ab...
The significance of cognitive function assessment in treatment-naïve high-grade glioma patients on clinical outcomes using neuropsychological tests: A review of current research.
e14022 Background: High-grade gliomas (HGGs), classified as WHO grades III and IV, represent over 50% of newly diagnosed malignant primary brain tumors, w...
Cervical cancer treatment patterns & outcomes in sub-Saharan Africa: Findings from a multi-institutional cancer dataset.
e17511 Background: Cervical cancer is a significant public health concern in Sub-Saharan Africa (SSA), where it remains the leading cause of cancer-relate...
Outcomes of patients treated for monomorphic B-cell post-transplant lymphoproliferative disorder: A single-center experience.
7069 Background: Patients (pts) with monomorphic B-cell post-transplant lymphoproliferative disorder (B-PTLD) have poor outcomes and high treatment-relate...
Actionability landscape and biomarker utility in a colorectal cancer alliance cohort: Initial results from the Know Your Biomarker program.
e15605 Background: Actionable biomarkers have a prominent role in frontline decision-making for pts with metastatic colorectal cancer (CRC). Strategies ta...
Racial differences in the prognostic value of Oncotype (RS) and MammaPrint (MP) in postmenopausal, estrogen receptor (ER)–positive, node-negative (N0) breast cancer (BC) patients with low genomic risk: A National Cancer Database (NCDB) study.
539 Background: Postmenopausal patients with ER+, HER2 negative, N0 BC often rely on genomic testing, such as RS or MP, to determine the benefit of chemot...
<sup>177</sup> Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).
5016 Background: LuPSMA improves progression-free survival (PFS) and overall survival (OS) in patients with mCRPC. Immune checkpoint inhibitors (ICI) have...
Use of immune checkpoint inhibitors as first line therapy for untreated, unresectable pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials.
e20098 Background: Malignant pleural mesothelioma represents an uncommon malignancy, typically found in adults with prior exposure to asbestos. Despite th...
Benmelstobart plus carboplatin/paclitaxel with or without anlotinib, followed by maintenance benmelstobart with or without anlotinib, as first-line treatment for advanced or recurrent endometrial cancer: A randomized, open-label, phase II trial.
5508 Background: Immunotherapy combined with chemotherapy has demonstrated efficacy in treating endometrial cancer (EC), with greater benefit in mismatch...
Impact of pembrolizumab on geriatric syndromes in older patients with NSCLC: A propensity-matched retrospective cohort study.
12045 Background: Non-small cell lung carcinoma (NSCLC) predominantly affects older adults (≥65 years), where immune checkpoint inhibitors (ICIs) are a ke...
Duration of response (DoR) following treatment with UGN-102 in patients with recurrent, low-grade, intermediate-risk, non-muscle invasive, bladder cancer: 18-month DoR data from the phase 3 ENVISION trial.
4598 Background: Low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) is a recurrent cancer inadequately controlled by the curren...
Concordance of circulating tumor DNA and tissue genomic profiling in ovarian cancer: Influencing factors and clinical significance.
5548 Background: Next-generation sequencing of plasma circulating tumor DNA (ctDNA) shows promise in ovarian cancer management as a minimally invasive alt...
Insight into the global mortality trends due to prostate cancer among the under-55 population: An analysis of the Global Burden of Disease-2021.
5109 Background: Prostate cancer (PC) is the most prevalent non-skin cancer among males, and it is increasingly diagnosed in those under 55. This younger...
Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study.
e16143 Background: Local recurrence is the main failure pattern after radical treatment of esophageal cancer. There is no uniform treatment specification...
Acolbifene vs tamoxifen for breast cancer prevention in premenopausal women at high risk for breast cancer.
TPS10628 Background: The TAM01 trial of low dose (5 mg) tamoxifen (LDTAM) vs placebo was associated with significant improvement in risk for breast cancer...
Comparison of surveillance circulating tumor DNA and Merkel polyomavirus antibody titer for detection of Merkel cell carcinoma recurrence.
9574 Background: Circulating tumor DNA (ctDNA) is emerging as a robust biomarker for detecting recurrences in Merkel cell carcinoma (MCC). This study aims...